Iron Path Capital, a private equity firm focused on lower-middle market investments, agreed to acquire the Glycolic Acid business of The Chemours Company, a global chemistry company, for $137m. "Creating a better world through the power of our chemistry requires a clear focus on where to play and how to win. While our goal is to position every one of our businesses for growth, over the past several months it became clear that PureTech Scientific and Iron Path Capital may be best positioned to take Glycolic Acid to the next level. We’re incredibly proud and appreciative of our Glycolic Acid team and wish them all the best in this exciting next chapter," Mark Newman, Chemours President and CEO.